
    
      This is an outpatient study in people who currently suffer a minimum of 2 migraines per
      month. During the study, participants will be instructed to use no more than 2 doses of the
      study drug INP104 within a 24-hour period, or 3 doses in a 7-day period. Participants will
      self-administer INP104 nasally and record their migraines in an eDiary.
    
  